Ask AI
ProCE Banner Activity

Emerging Therapies in the Treatment of Patients With Higher Risk MDS in Frontline and Post-HMA Failure Settings

Slideset Download

Download these slides from a live symposium for expert guidance on managing patients with either newly diagnosed or HMA-refractory higher risk MDS.

Released: December 09, 2022

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology, Clinical Trails Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Hematology, Department of Internal Medicine, Yale School of Medicine
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer M. Zeidan, MBBS, MHS: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka, Pfizer, Takeda, Trovagene; consultant: Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Cardinal Health, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, Tyme.